Skip to main content
Top
Published in: Osteoporosis International 4/2010

Open Access 01-04-2010 | Original Article

The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK

Authors: C. Cooper, M. Steinbuch, R. Stevenson, R. Miday, N. B. Watts

Published in: Osteoporosis International | Issue 4/2010

Login to get access

Abstract

Summary

We conducted a case–control study to examine osteonecrosis (ON) incidence, patient characteristics, and selected potential risk factors using two health record databases in the UK. Statistically significant risk factors for ON included systemic corticosteroid use, hospitalization, referral or specialist visit, bone fracture, any cancer, osteoporosis, connective tissue disease, and osteoarthritis.

Introduction

The purpose of this case–control study was to examine the incidence of osteonecrosis (ON), patient characteristics, and selected potential risk factors for ON using two health record databases in the UK: the General Practice Research Database and The Health Improvement Network.

Methods

ON cases (n = 792) were identified from 1989 to 2003 and individually matched (age, sex, and medical practice) up to six controls (n = 4,660) with no record of ON. Possible risk factors were considered for inclusion based on a review of published literature. Annual incidence rates were computed, and a multivariable logistic regression model was derived to evaluate selected risk factors.

Results

ON of the hip represented the majority of cases (75.9%). Statistically significant risk factors for ON were systemic corticosteroid use in the previous 2 years, hospitalization, referral or specialist visit, bone fracture, any cancer, osteoporosis, connective tissue disease, and osteoarthritis within the past 5 years. Only 4.4% of ON cases were exposed to bisphosphonates within the previous 2 years.

Conclusions

This study provides further perspective on the descriptive epidemiology of ON. Studies utilizing more recent data may further elucidate the understanding of ON key predictors.
Literature
1.
go back to reference Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124PubMed Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124PubMed
3.
go back to reference Mont MA, Payman RK, Laporte DM, Petri M, Jones LC, Hungerford DS (2000) Atraumatic osteonecrosis of the humeral head. J Rheumatol 27(7):1766–73PubMed Mont MA, Payman RK, Laporte DM, Petri M, Jones LC, Hungerford DS (2000) Atraumatic osteonecrosis of the humeral head. J Rheumatol 27(7):1766–73PubMed
4.
go back to reference Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28(4):761–5PubMed Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28(4):761–5PubMed
5.
go back to reference Abu-Shakra M, Buskila D, Shoenfeld Y (2003) Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25(1):13–24CrossRefPubMed Abu-Shakra M, Buskila D, Shoenfeld Y (2003) Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25(1):13–24CrossRefPubMed
6.
go back to reference Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed
7.
go back to reference Calvo-Alén J, McGwin G, Toloza S, Fernández M, Roseman JM, Bastian HM, Cepeda EJ, González EB, Baethge BA, Fessler BJ, Vilá LM, Reveille JD, Alarcón GS, LUMINA Study Group (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–90CrossRefPubMed Calvo-Alén J, McGwin G, Toloza S, Fernández M, Roseman JM, Bastian HM, Cepeda EJ, González EB, Baethge BA, Fessler BJ, Vilá LM, Reveille JD, Alarcón GS, LUMINA Study Group (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–90CrossRefPubMed
8.
go back to reference Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case–control study. J Rheumatol 35(4):691–5PubMed Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case–control study. J Rheumatol 35(4):691–5PubMed
9.
go back to reference van Staa TP, Cooper C, Leufkens HG, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18(5):913–8CrossRefPubMed van Staa TP, Cooper C, Leufkens HG, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18(5):913–8CrossRefPubMed
10.
go back to reference van Staa TP, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 3(1):15–21CrossRef van Staa TP, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 3(1):15–21CrossRef
11.
go back to reference van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9(5):359–66CrossRefPubMed van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9(5):359–66CrossRefPubMed
12.
go back to reference Wurst KE, Ephross SA, Loehr J, Clark DW, Guess HA (2007) The utility of the general practice research database to examine selected congenital heart defects: a validation study. Pharmacoepidemiol Drug Saf 16(8):867–77CrossRefPubMed Wurst KE, Ephross SA, Loehr J, Clark DW, Guess HA (2007) The utility of the general practice research database to examine selected congenital heart defects: a validation study. Pharmacoepidemiol Drug Saf 16(8):867–77CrossRefPubMed
13.
go back to reference Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ (2008) How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database. Arthritis Rheum 59(9):1314–21CrossRefPubMed Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ (2008) How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database. Arthritis Rheum 59(9):1314–21CrossRefPubMed
14.
go back to reference Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16(4):393–401CrossRefPubMed Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16(4):393–401CrossRefPubMed
15.
go back to reference Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS (1998) Avascular necrosis following bone marrow transplantation: a case–control study. Bone 22(1):67–71CrossRefPubMed Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS (1998) Avascular necrosis following bone marrow transplantation: a case–control study. Bone 22(1):67–71CrossRefPubMed
16.
go back to reference Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42(5):841–7CrossRefPubMed Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42(5):841–7CrossRefPubMed
17.
go back to reference Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144(10):753–61PubMed Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144(10):753–61PubMed
18.
go back to reference Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–34CrossRefPubMed Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–34CrossRefPubMed
19.
go back to reference Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–7CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–7CrossRefPubMed
20.
go back to reference Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E (2005) Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 23(22):5217–23CrossRefPubMed Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E (2005) Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 23(22):5217–23CrossRefPubMed
Metadata
Title
The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK
Authors
C. Cooper
M. Steinbuch
R. Stevenson
R. Miday
N. B. Watts
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-1003-1

Other articles of this Issue 4/2010

Osteoporosis International 4/2010 Go to the issue